The Centers for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced on Thursday ...
The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.
Centers for Medicare and Medicaid Services COO Kim Brandt talked about her agency’s use cases for artificial intelligence in the ongoing battle against fraudulent medical claims. The Centers for ...
The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed. A new solution with ...
Starting July 2026, Medicare will pilot the 'GLP-1 Bridge,' a temporary program allowing some retirees coverage for weight loss drugs like Wegovy and Zepbound. The initiative marks a shift from ...
The Centers for Medicare & Medicaid Services announced a seven-prong update to the Civil Money Penalty Reinvestment Program on Monday. The agency has increased the project funding cap by 20% and also ...
The Centers for Medicare & Medicaid Services (CMS) will extend its temporary Medicare GLP-1 Bridge program for obesity drug coverage through the end of 2027, delaying the launch of a longer-term model ...
Congress has an obligation to direct the Centers for Medicare and Medicaid Services to partner with state Medicaid leaders ...
Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...
The Trump administration will require all 50 states to explain their plans to revalidate some of their Medicaid providers in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results